T-cell–redirecting bispecific antibodies in multiple myeloma: a revolution?
Philippe Moreau, Cyrille Touzeau
Abstract
Bispecific antibodies are monoclonal antibodies targeting both a surface molecule on the malignant plasma cells and CD3 on T cells, leading to tumor cell death by activated T cells. Bispecific antibodies targeting B-cell maturation antigen, GPRC5D or FcRH5, demonstrated promising efficacy with favorable safety profile in patients with triple-class refractory multiple myeloma. This novel immunotherapeutic modality will likely change the treatment paradigm in the coming years.
Topics & Concepts
Multiple myelomaBispecific antibodyAntibodyMedicineCancer researchDaratumumabImmunologyBortezomibMonoclonal antibodyCAR-T cell therapy researchMonoclonal and Polyclonal Antibodies ResearchMultiple Myeloma Research and Treatments